Secukinumab provides better relief from the impact of psoriasis on daily activities and personal relationships than etanercept: results of two phase 3 placebo-controlled randomized clinical trials in moderate-to-severe psoriasis.
about
The impact of biologic agents on health-related quality of life outcomes in patients with psoriasis.Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than ustekinumab in patients with moderate-to-severe plaque psoriasis: 52-week results from the CLEAR study.Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis.
P2860
Secukinumab provides better relief from the impact of psoriasis on daily activities and personal relationships than etanercept: results of two phase 3 placebo-controlled randomized clinical trials in moderate-to-severe psoriasis.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Secukinumab provides better re ...... moderate-to-severe psoriasis.
@en
Secukinumab provides better re ...... moderate-to-severe psoriasis.
@nl
type
label
Secukinumab provides better re ...... moderate-to-severe psoriasis.
@en
Secukinumab provides better re ...... moderate-to-severe psoriasis.
@nl
prefLabel
Secukinumab provides better re ...... moderate-to-severe psoriasis.
@en
Secukinumab provides better re ...... moderate-to-severe psoriasis.
@nl
P2093
P2860
P1476
Secukinumab provides better re ...... moderate-to-severe psoriasis.
@en
P2093
Howard Sofen
Judit Nyirady
Margaret Mordin
Neil J Korman
Nicole Williams
Phoebe Rich
Scott Fretzin
Stephen Tyring
Vivian Herrera
P2860
P304
P356
10.1080/09546634.2016.1255306
P577
2016-11-11T00:00:00Z